Aurora Spine Corporation (ASG.V)
CAD 0.43
(1.18%)
CAD 0.43
(1.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -446.19 Thousand USD | -9.64% |
| 2022 | -469.27 Thousand USD | 78.6% |
| 2021 | -1.9 Million USD | -231.38% |
| 2020 | -573.85 Thousand USD | 17.17% |
| 2019 | -692.83 Thousand USD | -179.45% |
| 2018 | 872 Thousand USD | 164.36% |
| 2017 | -1.26 Million USD | -58.22% |
| 2016 | -856.31 Thousand USD | 66.76% |
| 2015 | -2.13 Million USD | 63.83% |
| 2014 | -7.12 Million USD | 0.0% |
| 2012 | -1.44 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 76.4 Thousand USD | 43.64% |
| 2024 Q2 | 98.98 Thousand USD | 29.54% |
| 2024 Q3 | 351.74 Thousand USD | 255.37% |
| 2023 Q2 | -195.39 Thousand USD | 50.85% |
| 2023 Q4 | 53.19 Thousand USD | -43.15% |
| 2023 Q3 | 93.56 Thousand USD | 147.89% |
| 2023 FY | - USD | -9.64% |
| 2023 Q1 | -397.56 Thousand USD | 13.54% |
| 2022 Q2 | 68.91 Thousand USD | 136.07% |
| 2022 Q1 | -191.05 Thousand USD | 80.05% |
| 2022 Q4 | -459.82 Thousand USD | -508.04% |
| 2022 FY | - USD | 78.6% |
| 2022 Q3 | 112.69 Thousand USD | 63.53% |
| 2021 FY | - USD | -231.38% |
| 2021 Q1 | -215.08 Thousand USD | 75.13% |
| 2021 Q3 | -198.46 Thousand USD | 62.57% |
| 2021 Q4 | -957.84 Thousand USD | -382.62% |
| 2021 Q2 | -530.28 Thousand USD | -146.54% |
| 2020 Q2 | 153.93 Thousand USD | 148.68% |
| 2020 Q4 | -864.99 Thousand USD | -290.03% |
| 2020 FY | - USD | 17.17% |
| 2020 Q3 | 455.17 Thousand USD | 195.7% |
| 2020 Q1 | -316.21 Thousand USD | 63.03% |
| 2019 Q2 | 233.34 Thousand USD | 243.49% |
| 2019 FY | - USD | -179.45% |
| 2019 Q4 | -855.24 Thousand USD | -515.88% |
| 2019 Q3 | -138.86 Thousand USD | -159.51% |
| 2019 Q1 | 67.93 Thousand USD | -50.52% |
| 2018 Q4 | 137.3 Thousand USD | -64.39% |
| 2018 FY | - USD | 164.36% |
| 2018 Q1 | 59.16 Thousand USD | 108.86% |
| 2018 Q2 | 290.01 Thousand USD | 390.21% |
| 2018 Q3 | 385.52 Thousand USD | 32.93% |
| 2017 Q1 | -364.13 Thousand USD | 22.0% |
| 2017 FY | - USD | -58.22% |
| 2017 Q2 | -212.8 Thousand USD | 41.56% |
| 2017 Q4 | -667.87 Thousand USD | -506.78% |
| 2017 Q3 | -110.06 Thousand USD | 48.28% |
| 2016 Q1 | -115.71 Thousand USD | 80.06% |
| 2016 Q3 | -309.93 Thousand USD | -992.98% |
| 2016 Q4 | -466.86 Thousand USD | -50.63% |
| 2016 Q2 | 34.7 Thousand USD | 129.99% |
| 2016 FY | - USD | 66.76% |
| 2015 Q4 | -580.18 Thousand USD | -36.14% |
| 2015 Q3 | -426.15 Thousand USD | -63.24% |
| 2015 FY | - USD | 63.83% |
| 2015 Q2 | -261.05 Thousand USD | 76.34% |
| 2015 Q1 | -1.1 Million USD | 48.77% |
| 2014 Q1 | -1.23 Million USD | 0.0% |
| 2014 Q2 | -1.42 Million USD | -15.61% |
| 2014 Q3 | -2.31 Million USD | -62.46% |
| 2014 Q4 | -2.15 Million USD | 6.89% |
| 2014 FY | - USD | 0.0% |
| 2013 Q3 | -636.12 Thousand USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | -261.35 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Perimeter Medical Imaging AI, Inc. | -17.91 Million CAD | 97.51% |
| Therma Bright Inc. | -3.67 Million CAD | 87.872% |
| Theralase Technologies Inc. | -4.25 Million CAD | 89.512% |
| VentriPoint Diagnostics Ltd. | -4.73 Million CAD | 90.584% |